More is being done than ever before to monetise neglected pharma IP
Roivant’s most recent spinout shows that it is still on the hunt for deprioritised life sciences patents
To read more
Register for limited access
Register to receive our newsletter and gain limited access to subscriber content.
Subscribe to unlock unlimited access
Get news, unique commentary, expert analysis and essential resources from the IAM experts.